FDA Cites Boston Scientific For GMP Violations In Warning Letter
Boston Scientific plans to meet with FDA the week of June 6 to discuss corrective measures to fix "serious regulatory problems" with the firm's Vaxcel low profile infusion ports
Boston Scientific plans to meet with FDA the week of June 6 to discuss corrective measures to fix "serious regulatory problems" with the firm's Vaxcel low profile infusion ports